BridgeBio to Present Acoramidis Data at AHA 2026

BridgeBio Pharma will share acoramidis and ATTR-CM research at the American Heart Association Scientific Sessions in Chicago this November.

Updated on Nov. 3, 2026 in Heart Disease

Bold flat-color editorial illustration of a smooth amber capsule beside a coil of translucent tubing on a cream field, evoking clinical drug research. — BridgeBio Pharma will present two moderated and three standard posters on its heart-drug acoramidis and ATTR-CM at the American Heart Association meeting in Chicago, November 6-9. AI Illustration. Upload story photo >

BridgeBio Pharma will present data on acoramidis, marketed as Attruby in the U.S., at the American Heart Association Scientific Sessions 2026 in Chicago, Illinois, November 6-9, 2026. The company will share two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), including an Abbott Laboratories-led poster on transthyretin detection assays.

Why it matters

ATTR-CM is a progressive heart condition, and the presentations will add to the clinical record for a therapy already approved in the United States, the European Union, and several other countries. The sessions give cardiologists and researchers a venue to compare acoramidis data with other approaches to treating the disease.

In the ATTRibute-CM trial, diarrhea occurred in 11.6% of Attruby patients versus 7.6% of placebo patients, and upper abdominal pain in 5.5% versus 1.4%. The poster results on these safety measures have not yet been presented, so the full picture remains pending.

The players

BridgeBio Pharma

BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetic conditions, with headquarters in Palo Alto, California, and multiple approved products.

Abbott Laboratories

Abbott Laboratories is a large multinational healthcare company known for diagnostics, medical devices, and nutrition products.

American Heart Association

The American Heart Association is a leading U.S. nonprofit focused on cardiovascular health research, education, and advocacy.

The details

BridgeBio will present two moderated posters and three standard posters on acoramidis and ATTR-CM during the sessions, with one poster led by Abbott Laboratories on transthyretin detection assays. Acoramidis is an orally administered, selective small molecule transthyretin stabilizer, and the company says it aims for near-complete stabilization of at least 90%.

November 6-9, 2026: American Heart Association Scientific Sessions in Chicago, Illinois.
November 8, 2026, 3:15 p.m. CT: Acoramidis ATTRibute-CM poster presentations.

Health Landscape

The presentations follow the FDA approval of Attruby as the first acoramidis product cleared in the United States for the cardiomyopathy of transthyretin-mediated amyloidosis. They add to a growing body of stabilizer-therapy data in ATTR-CM, a condition that has historically had few approved treatment options.

Patients with ATTR-CM and their clinicians will get more detail on how acoramidis performs and what side effects to expect, including diarrhea and upper abdominal pain. Those factors can shape decisions about whether a stabilizer therapy fits an individual's treatment plan.

The takeaway

Patients and families weighing treatment options for ATTR-CM should review the reported side-effect rates with their cardiologist before deciding on a therapy. Watching how the poster data compare with trial results can help set realistic expectations.

What happens next

The AHA Scientific Sessions run November 6-9, 2026, with the acoramidis ATTRibute-CM posters scheduled for November 8 at 3:15 p.m. CT and further moderated poster sessions on November 9.